CPC A23L 33/15 (2016.08) [A23D 9/00 (2013.01); A23L 7/115 (2016.08); A23L 33/105 (2016.08); A23L 33/155 (2016.08); A23L 33/16 (2016.08); A23V 2002/00 (2013.01)] | 2 Claims |
1. A method of treating Insulin Resistance in a user, comprising the steps of: obtaining a nutraceutical comprising a hydrophilic and lipophilic rice bran fraction prepared by an enzyme treatment comprising the use of a beta-glucanase enzyme, a thermotolerant protease enzyme mix derived from Carica papaya, and a thermostable alpha-amylase enzyme; and administering the nutraceutical to the user for a minimum of 90 days in an amount sufficient to treat Insulin Resistance in the user; wherein said fraction has a total Oxygen Radical Absorbance Capacity of at least 20,500 micromoles Trolox equivalents per 100 grams of said fraction, at least 10 milligrams of tocotrienols per 100 grams of said fraction, at least 149 milligrams of inositol per 100 grams of said fraction, and at least 248 milligrams of gamma-oryzanol per 100 grams of said fraction, 5-50 mg ferulic acid, and at least four phytosterols comprising β-Sitosterol, Stigmasterol, Campesterol, and Brassicasterol, and wherein said user has a fasting glucose level of between 100 to 120 mg/dL, triglycerides above 150 mg/dL, and a blood pressure above 130/85 mmHg, and wherein said phytosterols obtained from the species Oryza sativa or Oryza glaberrima.
|